GlassScriptPhysician profile
Vikram Dhillon
NPI 1760124325
$1,130.95
in general payments reported to CMS, 2019-2025
14 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.88 · 2023: $183 · 2024: $356 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.07 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.77 | 2022-2025 | Botox |
| Alexion Pharmaceuticals, INC. | $192.18 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $180.41 | 2023-2025 | Hyqvia, Alunbrig |
| Ucb, INC. | $96.53 | 2024-2025 | Rystiggo, Fintepla, Briviact |
| Biogen, INC. | $82.71 | 2025 | Tysabri, Vumerity |
| Daiichi Sankyo INC. | $53.37 | 2025 | Vanflyta, Enhertu |
| Genentech USA, INC. | $34.02 | 2023-2024 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Alnylam Pharmaceuticals INC. | $27.78 | 2025 | Onpattro |
| Pharmaessentia USA Corporation | $27.41 | 2025 | Besremi |
| Upsher-Smith Laboratories LLC | $26.54 | 2025 | |
| Sk Life Science, INC. | $25.36 | 2025 | |
| Incyte Corporation | $20.34 | 2024 | Jakafi |
| Tanabe Pharma America, INC. | $19.29 | 2024 | |
| Neurelis, INC. | $16.24 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.